Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fluidigm IPO cancellation drags down bottom line

This article was originally published in Clinica

Executive Summary

In what it described as an "unusual" move on its part, private integrated microfluidic chips manufacturer Fluidigm released its third-quarter results to the public in a bid to provide clarity on the firm’s financial situation. The South San Francisco, California-based company withdrew an IPO on the Nasdaq in September due to market instability, but has now disclosed its Q3 results as it felt “an obligation to update the financial world" after having promoted the company and its business prospects during its IPO roadshow. The firm recorded Q3 product revenue of $4.2m, an increase of 200% compared to the same period last year, helped by strong growth in sales of its BioMark genetic analysis system. However, Fluidigm’s bottom line suffered from the cancellation of the IPO, which cost the firm $3.6m in expenses. Net loss for the period was $8.9m, compared to the loss of $5.9m in Q3 2007.

You may also be interested in...

Alere aided by professional diagnostics sales in fourth quarter

Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.

Integra and Stout to work on expandable interbody device

Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.

Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials

Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts